Related Experiment Video

Updated: Oct 2, 2026

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

Model of inhibition of the NPM-ALK kinase activity by herbimycin A

Francesco Turturro1, Marilyn D Arnold, Audrey Y Frist

  • 1Human Gene Therapy Research Institute, John Stoddard Cancer Center, Des Moines, Iowa 50309, USA. turturfm@ihs.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 22, 2002
PubMed

Insights

Herbimycin A inhibits the NPM-ALK oncogene in anaplastic large cell lymphoma (ALCL) by blocking key cell pathways. Prolonged treatment may induce cell cycle arrest and apoptosis, suggesting potential therapeutic applications.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic large cell lymphoma (ALCL) with t(2;5) translocation expresses the oncogenic NPM-ALK fusion protein.
  • The ALK domain of NPM-ALK possesses tyrosine kinase activity, driving oncogenesis.
  • Protein tyrosine kinases are critical targets for cancer therapy.

Purpose of the Study:

  • To investigate the effect of Herbimycin A, a general protein tyrosine kinase inhibitor, on NPM-ALK activity.
  • To evaluate the antiproliferative and apoptotic effects of Herbimycin A in t(2;5)-ALCL cells.
  • To explore the potential of Herbimycin A as a therapeutic agent for ALCL.

Main Methods:

  • In vitro kinase assays to assess NPM-ALK autophosphorylation inhibition.
  • Cell culture of t(2;5)-ALCL cell lines (SUDHL-1).
  • Cell cycle analysis (G1 phase assessment) and Western blotting for NPM-ALK, Akt, and pAkt.
  • Apoptosis assays under prolonged and intermittent dosing regimens.

Main Results:

  • Herbimycin A specifically inhibited NPM-ALK autophosphorylation in vitro.
  • Treatment with Herbimycin A led to cell cycle arrest at the G1 phase in SUDHL-1 cells.
  • NPM-ALK, Akt, and pAkt protein levels were downregulated following Herbimycin A treatment.
  • Prolonged, intermittent administration of Herbimycin A induced apoptosis.

Conclusions:

  • Herbimycin A effectively inhibits NPM-ALK kinase activity and impacts downstream signaling pathways (Akt).
  • Sustained inhibition of NPM-ALK and Akt pathways by Herbimycin A can induce cell cycle arrest and apoptosis in ALCL cells.
  • Protein kinase inhibitors like Herbimycin A show promise as therapeutic strategies for t(2;5)-ALCL.

More Related Videos

A Flexible Low Cost Hydroponic System for Assessing Plant Responses to Small Molecules in Sterile Conditions11:27

A Flexible Low Cost Hydroponic System for Assessing Plant Responses to Small Molecules in Sterile Conditions

Published on: August 25, 2018

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...